^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FLT1 amplification

    i
    Other names: FLT1, FLT, VEGFR1, Fms-related tyrosine kinase 1
    Entrez ID:
    2321
    Related biomarkers:
    Expression
    Mutation
    Others
    over1year
    Identifying predictive biomarkers of apatinib in third-line treatment of advanced colorectal cancer through comprehensive genomic profiling. (PubMed, Anticancer Drugs)
    Our study described molecular profiles in CRC patients receiving apatinib treatment and identified FLT1 amplification as a potential predictive biomarker for poor efficacy of apatinib. Further studies are warranted to validate the use of FLT1 amplification during apatinib treatment.
    Journal • Tumor mutational burden • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • FLT1 (Fms-related tyrosine kinase 1)
    |
    PIK3CA mutation • FLT1 amplification
    |
    AiTan (rivoceranib)
    4years
    [VIRTUAL] FLT1 amplification predicts poor response in metastatic colorectal cancer patients treated with apatinib as 3rd line treatment. (ASCO 2020)
    Our study explored the potential predictive biomerkers for apatinib and revealed that FLT1 amplification might be a potential predictive biomarker for poor efficacy in mCRC patients treated with apatinib. FLT1 encodes VEGFR1, which could compete with VEGFR2 for binding with VEGF, potentially explaining the inferior response to apatinib observed in pateints harboring FLT1 amplification. Larger cohorts are needed to validate the finding.
    Clinical
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • FLT1 (Fms-related tyrosine kinase 1) • TCF7L2 (Transcription Factor 7 Like 2)
    |
    KRAS mutation • FLT1 amplification
    |
    AiTan (rivoceranib)